文献速递肿瘤 PET/CT核素与放射性配体治疗

177Lu-DOTATATE治疗后治疗相关骨髓增生异常综合征致DOTATATE PET/CT骨髓摄取弥漫性增高

Diffusely Increased Bone Marrow Uptake on DOTATATE PET/CT Due to PRRT-related Myelodysplasia Syndrome.
PubMed 文献 · Clin Nucl Med · 2025-08-20

报道一例转移性小肠神经内分泌肿瘤患者接受177Lu-DOTATATE治疗后5年随访,DOTATATE PET/CT显示已知转移灶局灶性摄取外新出现弥漫性骨髓摄取增高,骨髓活检证实为治疗相关骨髓增生异常综合征(t-MDS)。

要点

  • DOTATATE骨髓轻度摄取可因CD34造血祖细胞表达SST-2受体而属生理性。
  • 弥漫性骨髓摄取增高不应视为生理性,需警惕骨髓病变。
  • 本例骨髓活检证实为177Lu-DOTATATE治疗相关骨髓增生异常综合征。

核心结论

  • DOTATATE PET/CT新出现的弥漫性骨髓摄取增高不应视为生理性,提示骨髓病变,本例活检证实为治疗相关骨髓增生异常综合征。

研究设计与样本

  • 病例报告:一例既往接受177Lu-DOTATATE治疗的转移性小肠神经内分泌肿瘤患者,治疗后5年随访行DOTATATE PET/CT。

主要发现

  • 治疗后5年因乏力与背痛随访的DOTATATE PET/CT显示,除已知转移灶相应局灶性摄取外,新出现弥漫性骨髓摄取增高。
  • 骨髓活检证实为治疗相关骨髓增生异常综合征(t-MDS)。

关键数值与推荐

  • DOTATATE骨髓 faint/mild 摄取可因骨髓CD-34造血祖细胞存在SST-2受体而出现,属生理性;弥漫性骨髓摄取增高不视为生理性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report an unusual imaging finding on DOTATATE PET/CT in a patient with prior 177Lu-DOTATATE treatment for metastatic small bowel neuroendocrine tumor. Five years post-treatment follow-up DOTATATE PET/CT for fatigue and back pain showed new diffusely increased bone marrow uptake in addition to focal uptake corresponding to known metastases. Faint/mild bone marrow uptake of DOTATATE can be seen due to the presence of SST-2 receptor on CD-34 hematopoietic progenitor cells in the marrow, but diffusely increased marrow uptake, as in this case, was not deemed physiologic and was concerning for marrow pathology. Subsequent bone marrow biopsy confirmed therapy-related myelodysplastic syndrome (t-MDS).

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wu C, Menshikova E, Takalkar AM, et al. Diffusely Increased Bone Marrow Uptake on DOTATATE PET/CT Due to PRRT-related Myelodysplasia Syndrome. Clin Nucl Med. 2025. PMID: 40830914. doi:10.1097/RLU.0000000000006095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。